Stock CBIO CATALYST BIOSCIENCES
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases Catalyst Biosciences

Equities

CBIO

US14888D2080

Market Closed - Nasdaq
Other stock markets
 21:00:00 09/05/2024 BST 		5-day change 1st Jan Change
15.23 USD -2.93% Intraday chart for Catalyst Biosciences +8.01% +98.58%
2023 Catalyst Biosciences, Inc.(NasdaqCM:CBIO) dropped from NASDAQ Composite Index CI
2023 Beijing Continent Pharmaceutical Co., Ltd. completed the acquisition of Catalyst Biosciences, Inc. in a reverse merger transaction. CI

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Catalyst Biosciences : Gyre Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update - Form 8-K
PU
Catalyst Biosciences : Notification of Conclusion of License Agreement by Gyre Pharmaceuticals Co - Form 8-K
PU
Catalyst Biosciences : Investor presentation 556.8 KB
PU
Catalyst Biosciences : Investor presentation 556.2 KB
PU
Catalyst Biosciences : GNI Group Updates Other Income and Full Year 2023 Consolidated Earnings Forecasts - Form 8-K
PU
Catalyst Biosciences : GNI Group Updates Full Year 2023 Consolidated Earnings Forecast - Form 8-K
PU
Catalyst Biosciences : Change in Certifying Accountants - Form 8-K
PU
Catalyst Biosciences Announces Completion of Business Combination With Beijing Continent Pharmaceuticals and Implementation of Name Change and Reverse Stock Split
AQ
CATALYST BIOSCIENCES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Catalyst Biosciences, Inc. - CBIO
BU
CATALYST BIOSCIENCES, INC. : Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing (form 8-K)
AQ
CATALYST BIOSCIENCES, INC. : Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing (form 8-K)
AQ
CATALYST BIOSCIENCES, INC. : Entry into a Material Definitive Agreement, Financial Statements and Exhibits (form 8-K)
AQ
CATALYST BIOSCIENCES, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS. (form 10-K)
AQ
Catalyst Biosciences : Investor presentation 1.6 MB
PU
CATALYST BIOSCIENCES, INC. : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)
AQ
CATALYST BIOSCIENCES INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Catalyst Biosciences, Inc. - CBIO
PR
CATALYST BIOSCIENCES, INC. : Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Other Events, Financial Statements and Exhibits (form 8-K)
AQ
Catalyst Biosciences Provides Corporate Update
AQ
CATALYST BIOSCIENCES, INC. : Change in Directors or Principal Officers, Financial Statements and Exhibits (form 8-K)
AQ
CATALYST BIOSCIENCES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Catalyst Biosciences, Inc. - CBIO
BU
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. CBIO Stock
  4. News Catalyst Biosciences
  5. Press Releases